It’s been a while since I’ve pointed to any of Richard Lehman’s witticisms as he pores through medical journals each week, trying to make sense of what he reads, and trying to help us do so as well.
On Twitter today, somebody tweeted today that Lehman’s brain needs to be preserved in a jar so he can blog for the next 100 years. Someone else wrote “I find it almost impossible not to quote him.” I quote him as he lances The Lancet today:
Lancet 7 Dec 2013 Vol 382
The Lancet is a very odd journal, in case you hadn’t noticed. Some weeks it contains pharma-funded phase 2 trials of astounding clinical irrelevance; occasionally it contains important papers heralding major breakthroughs, or reporting massive RCTs; then there are some issues entirely devoted to health in a particular part of the globe you are unlikely to visit; last week the journal was all about sex and the British, in case you are thinking of having sex in Britain; and this week the entire research section is taken up with this analysis the safety and efficacy of drug-eluting stents in women, based on patient-level results from 26 randomised trials; plus a paper on risk stratification at diagnosis for children with hypertrophic cardiomyopathy. We seem to have wandered into the pages of Circulation rather than The Lancet. Anyway, the message from the stents-for-women analysis is that drug-eluting stents are safer than bare metal stents, and that second-generation drug-eluters are better than first generation. This is very much what pharma would like you to believe, so I am inclined to disbelieve it. But then neither I nor you, dear reader, are in a position to re-interrogate the data and the methods of 26 major trials. We must believe what we read, and buy the latest products.
—————————-
Follow us on Twitter:
https://twitter.com/garyschwitzer
https://twitter.com/healthnewsrevu
Opinions on other issues in news, journals, PR, advertising, marketing
A great read on this weekend’s NYT claims of a cure for Type 1.
Cure for Type 1 diabetes? We’ve been down this road before with NY Times https://www.healthnewsreview.org/2021/11/cure-for-type-1-diabetes-weve-been-down-this-road-before-with-ny-times/
"But it is the framing and the emphasis of the #journalism by a leading science journalist at a leading newspaper that demands scrutiny. It has an impact on readers and on sick people that may cause harm by promoting false hope about extremely preliminary research"
👍👏💪 truth https://twitter.com/garyschwitzer/status/1465399358137024518
Why we should still miss healthnewsreview. https://twitter.com/garyschwitzer/status/1465399358137024518
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like